Financial News · Live Terminal

Page 98 of 312

Bernstein Initiates Revolution Medicines at Market Perform

Revolution Medicines (RVMD) has an average rating of buy and mean price target of $182.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Financial News · Live Terminal

Bernstein Initiates Revolution Medicines at Market Perform

Barclays Initiates Coverage on Cleveland-Cliffs With Underweight

Bernstein Initiates Summit Therapeutics at Underperform

Loop Capital Initiates Bread Financial at Buy With $104 Price Target

Barclays Initiates Coverage on Agnico Eagle Mines With Overweight Rating

Tisco Securities Upgrades R&B Food Supply to Buy from Hold; Price Target is THB4.40

Kotak Securities Upgrades Sun TV Network to Buy from Add; Price Target is INR740

KGI Securities Downgrades Amata Corporation to Hold from Buy; Price Target is THB28

Needham Initiates Eos Energy Enterprises at Buy With $11 Price Target

MIDF Amanah Upgrades Telekom Malaysia to Buy from Neutral; Price Target is MYR8.31

MIDF Amanah Upgrades Ta Ann Holdings to Buy from Neutral; Price Target is MYR6.08

Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target

Wells Fargo Initiates Main Street Capital at Equalweight With $50 Price Target

Prabhudas Lilladher Downgrades Zee Entertainment Enterprises to Accumulate from Buy; Price Target is INR91

KGI Securities Upgrades Amata Corporation to Outperform from Neutral; Price Target is THB30

BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80

JPMorgan Upgrades Sweetgreen to Overweight From Neutral, Price Target is $13

BofA Securities Downgrades Inspire Medical Systems to Underperform From Neutral, Price Target is $39

Truist Upgrades Viking Holdings to Buy From Hold, Raises Price Target to $102 From $75

HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy

Bernstein Initiates Revolution Medicines at Market Perform

Barclays Initiates Coverage on Cleveland-Cliffs With Underweight

Bernstein Initiates Summit Therapeutics at Underperform

Loop Capital Initiates Bread Financial at Buy With $104 Price Target

Barclays Initiates Coverage on Agnico Eagle Mines With Overweight Rating

Tisco Securities Upgrades R&B Food Supply to Buy from Hold; Price Target is THB4.40

Kotak Securities Upgrades Sun TV Network to Buy from Add; Price Target is INR740

KGI Securities Downgrades Amata Corporation to Hold from Buy; Price Target is THB28

Needham Initiates Eos Energy Enterprises at Buy With $11 Price Target

MIDF Amanah Upgrades Telekom Malaysia to Buy from Neutral; Price Target is MYR8.31

MIDF Amanah Upgrades Ta Ann Holdings to Buy from Neutral; Price Target is MYR6.08

Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target

Wells Fargo Initiates Main Street Capital at Equalweight With $50 Price Target

Prabhudas Lilladher Downgrades Zee Entertainment Enterprises to Accumulate from Buy; Price Target is INR91

KGI Securities Upgrades Amata Corporation to Outperform from Neutral; Price Target is THB30

BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80

JPMorgan Upgrades Sweetgreen to Overweight From Neutral, Price Target is $13

BofA Securities Downgrades Inspire Medical Systems to Underperform From Neutral, Price Target is $39

Truist Upgrades Viking Holdings to Buy From Hold, Raises Price Target to $102 From $75

HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy